ADMA Biologics (NASDAQ:ADMA) Trading Up 5.3%

ADMA Biologics Inc (NASDAQ:ADMA) rose 5.3% during mid-day trading on Thursday . The stock traded as high as $2.61 and last traded at $2.59, approximately 1,159,800 shares changed hands during trading. A decline of 51% from the average daily volume of 2,371,081 shares. The stock had previously closed at $2.46.

ADMA has been the subject of several research reports. BidaskClub cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 29th. ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, HC Wainwright dropped their price objective on shares of ADMA Biologics from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, March 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $10.00.

The company has a current ratio of 6.12, a quick ratio of 2.33 and a debt-to-equity ratio of 3.23. The company has a market capitalization of $212.42 million, a price-to-earnings ratio of -2.88 and a beta of 2.31. The firm’s fifty day simple moving average is $2.94 and its two-hundred day simple moving average is $4.01.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, March 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The firm had revenue of $12.04 million during the quarter, compared to analyst estimates of $11.92 million. ADMA Biologics had a negative net margin of 164.50% and a negative return on equity of 167.18%. As a group, analysts forecast that ADMA Biologics Inc will post -0.5 EPS for the current fiscal year.

In related news, Director Lawrence P. Guiheen acquired 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were purchased at an average cost of $3.50 per share, for a total transaction of $70,000.00. Following the acquisition, the director now owns 70,000 shares in the company, valued at approximately $245,000. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam S. Grossman acquired 28,571 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was bought at an average price of $3.50 per share, for a total transaction of $99,998.50. Following the completion of the acquisition, the chief executive officer now owns 66,098 shares in the company, valued at approximately $231,343. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 5,123,698 shares of company stock worth $17,232,943. Company insiders own 15.20% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. acquired a new position in shares of ADMA Biologics in the 4th quarter worth approximately $40,000. Citigroup Inc. lifted its holdings in ADMA Biologics by 302.8% during the 4th quarter. Citigroup Inc. now owns 14,827 shares of the biotechnology company’s stock worth $60,000 after buying an additional 11,146 shares in the last quarter. Algert Global LLC acquired a new stake in ADMA Biologics during the 4th quarter worth approximately $70,000. Voya Investment Management LLC lifted its holdings in ADMA Biologics by 60.4% during the 3rd quarter. Voya Investment Management LLC now owns 18,688 shares of the biotechnology company’s stock worth $83,000 after buying an additional 7,038 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY acquired a new stake in ADMA Biologics during the 3rd quarter worth approximately $85,000. Hedge funds and other institutional investors own 54.73% of the company’s stock.

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Read More: Can individual investors take part in an IPO?

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.